Identification of New EGFR Inhibitors by Structure-Based Virtual Screening and Biological Evaluation

Authors

Shuyi Wang
Xiaotian Xu
Chuxin Pan
Qian Guo
Qinlan Li
Shanhe Wan
Zhonghuang Li
Jiajie Zhang
Xiaoyun Wu

Publication Date

2-4-2024

Journal

International Journal of Molecular Sciences

Abstract

Epidermal growth factor receptor (EGFR) inhibitors have been used in clinical for the treatment of non-small-cell lung cancer for years. However, the emergence of drug resistance continues to be a major problem. To identify potential inhibitors, molecular docking-based virtual screening was conducted on ChemDiv and Enamine commercial databases using the Glide program. After multi-step VS and visual inspection, a total of 23 compounds with novel and varied structures were selected, and the predicted ADMET properties were within the satisfactory range. Further molecular dynamics simulations revealed that the reprehensive compound ZINC49691377 formed a stable complex with the allosteric pocket of EGFR and exhibited conserved hydrogen bond interactions with Lys 745 and Asp855 of EGFR over the course of simulation. All compounds were further tested in experiments. Among them, the most promising hit ZINC49691377 demonstrated excellent anti-proliferation activity against H1975 and PC-9 cells, while showing no significant anti-proliferation activity against A549 cells. Meanwhile, apoptosis analysis indicated that the compound ZINC49691377 can effectively induce apoptosis of H1975 and PC-9 cells in a dose-dependent manner, while having no significant effect on the apoptosis of A549 cells. The results indicate that ZINC49691377 exhibits good selectivity. Based on virtual screening and bioassays, ZINC4961377 can be considered as an excellent starting point for the development of new EGFR inhibitors.

Keywords

Humans, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Cell Line, Tumor, Cell Proliferation, ErbB Receptors, Lung Neoplasms, Molecular Docking Simulation, Molecular Dynamics Simulation, Protein Kinase Inhibitors

Comments

Supplementary Materials

PMID: 38339163